ACT-903 / Alpha Cancer Technologies - LARVOL DELTA

Alpha Cancer Technologies Presents New Data from ACT-903, an AFP-Maytansine Conjugate, in Online Publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Businesswire) - "Alpha Cancer Technologies...announced details from the company’s abstract published as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting....Statistically significant dose-dependent reduction in tumor volume across all treatment groups compared to control in an ovarian xenograft model. Complete elimination of tumor and 100% survival observed in the group receiving optimal treatment regimen....ACT plans to submit an Investigational New Drug (IND) application for ACT-903 in 2024."

IND • Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

High anti-tumor activity of a novel alpha-fetoprotein-maytansinoid conjugate targeting alpha-fetoprotein receptors in colorectal cancer xenograft model. (PubMed, Cancer Cell Int) - "Studies were performed to investigate the use of recombinant human AFP (ACT-101) conjugated with maytansinoid toxins for targeted toxin delivery to cancer. No obvious signs of toxicity were seen in any of the treated groups. Observed efficacy and excellent tolerability of ACT-903 in these xenograft models support advancing the development of ACT-903 toward clinical use."

Journal • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • AFP

Alpha Cancer Technologies (ACT) Publishes Pre-Clinical Study Results in Cancer Cell International Demonstrating Excellent Safety and Significant Anti-Tumor Activity from the Company’s Next Generation ADC, ACT-903 (Businesswire) - "Alpha Cancer Technologies...announced the publication of pre-clinical study results in Cancer Cell International highlighting the company’s recombinant human AFP (ACT-101) conjugate with maytansine in mouse xenograft models of colorectal cancer. Results from the study demonstrate the exceptional safety profile and potent anti-tumor activity of multiple ACT-101 conjugates through the successful targeting of the alpha fetoprotein receptor uniquely located on cancerous cells and myeloid-derived suppressor cells (MDSCs)....The anti-tumor effects of the conjugate selected for further development, ACT-903, persisted after treatment discontinuation, with tumors becoming undetectable in 9 of 10 mice, and all 10 mice surviving through Day 60 with no obvious signs of toxicity."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

An alpha-fetoprotein-maytansine conjugate for the treatment of AFP receptor expressing tumors. (ASCO 2022) - "By conjugating a novel maytansinoid toxin to a recombinant form of human AFP (ACT-101), we can selectively deliver the toxin to cancer and MDSC cells while sparing normal cells, thereby enabling a combination of targeted and immune activating approaches against the tumor. The efficacy and tolerability of ACT-903 in an animal tumor model supports advancing this conjugate toward clinical use with a regimen of either once a week or once every other week administration."

Oncology • AFP